Month: March 2026

Q4 Net Sales Increase of 24.3% to $1.73 Billion; Q4 Comparable Sales Increase of 15.4% FY 2025 Net Sales Increase of 22.9% to $4.76 Billion; FY 2025 Comparable Sales Increase of 12.8% Q4 GAAP Diluted EPS Increase of 26.3% to $4.28, Q4 Adjusted Diluted EPS Increase of 23.9% to $4.31 FY 2025 GAAP Diluted EPS Increase of 40.7% to $6.47, FY 2025 Adjusted Diluted EPS Increase of 32.3% to $6.67 Provides First Quarter and Fiscal 2026 Outlook PHILADELPHIA, PA, March 18, 2026 (GLOBE NEWSWIRE) — Five Below, Inc. (NASDAQ: FIVE) today announced financial results for the fourth quarter and full year of fiscal 2025 ended January 31, 2026. For the fourth quarter ended January 31, 2026:Net sales increased by 24.3% to $1.73 billion from $1.39 billion in the fourth quarter of fiscal 2024; comparable sales increased by 15.4%. The Company opened...

Record Full Year Revenues, Processing Volume (up 19%) and Transactions Processed (up 30%) SAN ANTONIO, March 18, 2026 (GLOBE NEWSWIRE) — Usio, Inc. (“Usio” or the “Company”) (Nasdaq: USIO), a leading Fintech company that operates a full stack of integrated, cloud-based electronic payment and embedded financial solutions, today announced financial results for the fourth quarter and year ended December 31, 2025. Louis Hoch, Chairman and Chief Executive Officer of Usio, said, “I am pleased to report another year of positive Adjusted EBITDA1 and Cash Flow from Operations on solid revenue growth. In addition, we increased total processing volume to $8.4 billion, up 19% compared to 2024. As anticipated, the second half of the year was much improved from the first half, especially the fourth quarter, where...

Record results and outlook reflect strategic value of memory in AI era BOISE, Idaho, March 18, 2026 (GLOBE NEWSWIRE) — Micron Technology, Inc. (Nasdaq: MU) today announced results for its second quarter of fiscal 2026, which ended February 26, 2026. Fiscal Q2 2026 highlightsRevenue of $23.86 billion versus $13.64 billion for the prior quarter and $8.05 billion for the same period last year GAAP net income of $13.79 billion, or $12.07 per diluted share Non-GAAP net income of $14.02 billion, or $12.20 per diluted share Operating cash flow of $11.90 billion versus $8.41 billion for the prior quarter and $3.94 billion for the same period last year“Micron set new records across revenue, gross margin, EPS, and free cash flow in fiscal Q2, driven by a strong demand environment, tight industry supply, and our strong execution,...

MOUNTAIN VIEW, Calif., March 18, 2026 (GLOBE NEWSWIRE) — Heartflow, Inc. (Heartflow) (Nasdaq: HTFL), the leader in AI technology for coronary artery disease (CAD), today reported financial results for the fourth quarter and full year ended December 31, 2025. Fourth Quarter 2025 HighlightsTotal revenue of $49.1 million, a 40% increase year-over-year Gross margin of 79.5%, non-GAAP gross margin of 79.9% Net operating loss of $17.8 million, non-GAAP net operating loss of $12.5 million U.S. installed base of 1,465 accounts as of December 31, 2025 U.S. Plaque installed base of 489 accounts as of December 31, 2025 Aetna began coverage of Heartflow Plaque Analysis, bringing total U.S. covered lives for Plaque to approximately 75%2026 Annual GuidanceTotal revenue of $218 million to $222 million (approximately 24% to 26% growth year-over-year) Non-GAAP...

On track to complete enrollment for the Phase 3 PROACT 1 accelerated approval analysis of rilparencel in mid-2026; anticipate pivotal topline results in Q2 2027 In a July 2025 Type B meeting, aligned with FDA on the accelerated approval pathway for rilparencel using eGFR slope as the surrogate endpoint Presented positive results from the Phase 2 REGEN-007 study of rilparencel as a late-breaking clinical trial at ASN Kidney Week 2025 followed by a peer-reviewed publication in CJASN Ended 2025 with $270.0 million in cash and cash equivalents and marketable securities, supporting operations into mid-2027WINSTON-SALEM, N.C., March 18, 2026 (GLOBE NEWSWIRE) — ProKidney Corp. (Nasdaq: PROK) (“ProKidney” or the “Company”), a leading late clinical-stage cell therapy company focused on chronic kidney disease (CKD), today reported...